BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.
Amazon’s Boon for Diabetes Patients, Streamlining Pharmacy Discounts
Amazon.Com Inc's (NASDAQ: AMZN) online pharmacy launched a new initiativ
BTIG Downgrades T2 Biosystems to Neutral
BTIG analyst Mark Massaro downgrades T2 Biosystems (NASDAQ:TTOO) from Buy to Neutral.
Related Posts
Sensient Technologies Q2 Earnings Miss Estimates, Lowers FY23 EPS Outlook
Sensient Technologies Corporation (NYSE: SXT) reported second-quarter revenues of $374.31 million, up 0.7% year over year. Revenues missed estimates of $382.62 million.
Oncocyte Announces Date Change For Q4 And FY22 Earnings Call, Will Now Report On Monday, April 3, 2023
Oncocyte Corporation (NASDAQ:OCX), a precision diagnostics company, announced today that it has changed the date of its previously announced earnings conference call. It will now report its fourth
Actinium Highlights Administration Of Targeted Radiotherapy Iomab-B Across Various BMT Centers With Ease And Without Increasing Radiation Exposure Risks To Treating Nursing Staff In The Pivotal Phase 3 SIERRA Trial At The 48th Annual ONS Congress
- 24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or refractory acute